Cargando…
Transcriptomic signature of Bexarotene (Rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models
BACKGROUND: The rexinoid bexarotene (LGD1069, Targretin) is a highly selective retinoid × receptor (RXR) agonist that inhibits the growth of pre-malignant and malignant breast cells. Bexarotene was shown to suppress the development of breast cancer in transgenic mice models without side effects. The...
Autores principales: | Abba, Martin C, Hu, Yuhui, Levy, Carla C, Gaddis, Sally, Kittrell, Frances S, Zhang, Yun, Hill, Jamal, Bissonnette, Reid P, Medina, Daniel, Brown, Powel H, Marcelo Aldaz, C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563021/ https://www.ncbi.nlm.nih.gov/pubmed/18786257 http://dx.doi.org/10.1186/1755-8794-1-40 |
Ejemplares similares
-
A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
por: Yen, W-C, et al.
Publicado: (2006) -
Identification of biomarkers regulated by rexinoids (LGD1069, LG100268 and Ro25-7386) in human breast cells using Affymetrix microarray
por: SEO, HYE-SOOK, et al.
Publicado: (2015) -
The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice
por: Li, Y, et al.
Publicado: (2008) -
Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models
por: Rajkumar, Lakshmanaswamy, et al.
Publicado: (2007) -
Conditional Wwox Deletion in Mouse Mammary Gland by Means of Two Cre Recombinase Approaches
por: Ferguson, Brent W., et al.
Publicado: (2012)